Genetically modified organisms: an analysis of the regulatory framework currently employed within the European Union.
BACKGROUND
Genetic engineering technology is starting to bring many commercial products to the market. These genetically modified organisms (GMOs) and their derived products are subject to topical debate as to their benefits and risks. The strengths and weaknesses of the regulatory framework that controls their development and application is central to the question of whether this technology poses significant risk to the public health during this critical phase of its evolution.


METHODS
A critical review was carried out of the legal framework regulating the contained use, deliberate release and some aspects of consumer protection relevant to the control of GMOs in Europe and the United Kingdom.


RESULTS
The current legal framework is failing to provide a speed of adaptation commensurate with the development of the science of genetic engineering; failing to properly respond to democratic control; failing to resolve significant conflict between the protection of free markets and protection of public health and the environment; and failing to implement obligations on biodiversity.


CONCLUSIONS
The present legal framework must be replaced. Current European Union proposals for new standards of regulation are welcome, but provide only for further incremental change, and do not address some significant fundamental flaws in our current laws.
Gent
R N
RN
Public Health and Health Professional Development Unit, Lancaster University.
D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D017753:Ecosystem; D004782:Environmental Health; D005062:European Union; D005818:Genetic Engineering / Q000009:adverse effects / Q000331:legislation & jurisprudence* / Q000592:standards* / Q000639:trends; D006801:Humans; D008389:Marketing of Health Services; D013673:Technology Assessment, Biomedical